Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
INO-3605 · 1 trial · 1 indication
Frequency and severity of local and systemic reactogenicity signs and symptoms, adverse events and serious adverse events
| Arm | Type | Description |
|---|---|---|
| Arm A - 0.9mg of INO-3605 | EXPERIMENTAL | - |
| Arm B - 0.9mg of INO-3609 | EXPERIMENTAL | - |
| Arm C- 0.9mg of INO-3401 | EXPERIMENTAL | - |
| Arm D- 0.3mg of INO-3609 | EXPERIMENTAL | - |
| Arm E - 0.45mg each INO-3605 , INO-3609 | EXPERIMENTAL | - |
| Arm F - 0.3mg each of INO-3401,INO-3605,INO-3609 | EXPERIMENTAL | - |
| Arm G - 0.9mg of INO-3609 | EXPERIMENTAL | - |
| Arm H - 0.9mg of INO-3609 | EXPERIMENTAL | - |
| Arm I - Seasonal influenza vaccine | ACTIVE_COMPARATOR | - |
| Arm J - 1.8mg of INO-3609 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| INO-3605 | BIOLOGICAL | 0.9mg of INO-3605 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24. |
| INO-3609 | BIOLOGICAL | 0.9mg of INO-3609 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24. |
| INO-3401 | BIOLOGICAL | 0.9mg of 3401 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24. |
| INO-3605 AND INO-3609 | BIOLOGICAL | 0.45mg each of INO-3605 AND INO-3609 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24. |
| INO-3510 | BIOLOGICAL | 0.3mg each of INO-3605, INO-3609 AND INO-3401 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24. |
| Seasonal Influenza vaccine | BIOLOGICAL | 0.5ml of vaccine delivered IM |
Inclusion Criteria: * Written informed consent in accordance with institutional guidelines. If required by local law, candidates must also authorize the release and use of protected health information (PHI); * Adults of either gender 18-55 years of age at entry; * Healthy subjects as judged by the ...
INO-3605 is an investigational DNA vaccine being developed by Inovio Pharmaceuticals, Inc. (INO). It is designed for the prevention of disease caused by H1 and H5 influenza virus. The drug is currently in Phase 1 clinical development and has completed one trial.
INO-3605 is used for the prevention of disease caused by H1 and H5 influenza virus. It is being studied in healthy volunteers as a preventive measure against these influenza strains. The drug is currently in Phase 1 clinical development.
INO-3605 is developed by Inovio Pharmaceuticals, Inc., a biopharmaceutical company traded under the ticker symbol INO. The company is conducting clinical trials to evaluate the safety and immunogenicity of this investigational DNA vaccine.
INO-3605 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 1 trial has been completed, and the drug remains under evaluation for the prevention of H1 and H5 influenza.
INO-3605 has been studied in one completed Phase 1 clinical trial, NCT01405885, titled 'A Study of DNA Vaccine With Electroporation for the Prevention of Disease Caused by H1 and H5 Influenza Virus.' The trial enrolled 116 healthy volunteers in the United States.
INO-3605 is a DNA vaccine that is administered with electroporation, as described in the clinical trial NCT01405885. The trial evaluates the vaccine's ability to prevent disease caused by H1 and H5 influenza virus when delivered via this method.